سلو ديرالين ١٦٠ ملغ

المعلومات الرئيسية

  • اسم تجاري:
  • سلو ديرالين ١٦٠ ملغ
  • الشكل الصيدلاني:
  • CAPSULES
  • طريقة التعاطي:
  • PER OS
  • يسخدم من اجل:
  • البشر
  • نوع الدواء:
  • المخدرات الوباتشيك
  • المصنعة من قبل:
  • TEVA PHARMACEUTICAL INDUSTRIES LTD

المستندات

الأقلمة

  • متاح في:
  • سلو ديرالين ١٦٠ ملغ
    إسرائيل
  • اللغة:
  • العربية

معلومات العلاجية

  • المجموعة العلاجية:
  • PROPRANOLOL
  • الخصائص العلاجية:
  • Management of angina pectoris. Control of essential and renal hypertension and essential tremor.As an adjunct in the management of tachycardias and arrhythmias due to thyrotoxicosis and thyrotoxic crises. Migraine prophylaxis.

معلومات أخرى

الحالة

  • المصدر:
  • Ministry of Health - State of Israel
  • تخويل:
  • 48352332000
  • تاريخ الترخيص:
  • 01-05-2010
  • اخر تحديث:
  • 09-08-2016

معلومات المرضى النشرة

Deralin-07-05-12-AH/JO 

® ! "   ® #! "

Propranolol HCl 10 mg Propranolol HCl 40 mg

Lactose monohydrate, magnesium stearate, gelatin, carmine powder.  

®

"   ®

"

Propranolol HCl 80 mg Propranolol HCl  160 mg

In a sustained release form In a sustained release form

Microcrystalline cellulose, ethylcellulose, hypromellose, erythrosine, black iron oxide, red iron oxide, titanium 

dioxide, water, gelatin.  

"

" ! " # $ # % & Beta- blockers ' &

# # % & ' ( ) ( # &#

&

" " ! & !

& & ! # ! (

* # (

& % # '

! *# + phaechromocytoma # % &

* ! " ) '

! *# + " % & " '

" #*#

! *# + & ! # & % ! ' ( + ( (

& ( ! & % ' ( ! * "*# +

& & $

& # & & ( # ! # &

# & & ( # &

* & ) ( ( (

# # * & & * &

& & # & ( # & )& * & & &

& *# + ! # & % # # ' ( # & & * &

& &#

"

& ( !

* & # ! & # $ & # & $ (

" # % ) ' ( " ! % ! ( ( # ( # (

" # % ' (

& ' ( " % ' ( !# (

" ' ( % ) ' # % ! '

& & & " & ,!#

& " " # & % Raynaud ' (

& + ! ( &

" # + # ! % ! ! ' ( ! % (

& & ' ( ! $ & ( % ! *# +   ' (

& # ( " # ( ( ( # % ! ' ( ( ( ( #&

& % ! ! ' ( & # ! % ! ' (

& & !

myasthenia gravis ' ( , # , % &

& & '

! # ! " & ( ( & ( ( (

" " ( # ! '

& # !

& ' # +

& ( ! # ( ( % # ' # + -

& # " & ( * # ( )& * & &

" # & &

" # # & * $ # &

& % ' )

!& -

" " #

& & &

&

........................................ ...

...........................................

& "& ! * " & #

& # &

& & # # ( # + ( + *

&

& ' ) & & *

& #*# + + *# +

25 C

" #! ( # * #

)& * &

023 52 21382 00

105 37 21381 00

048 34 23318 00

048 35 23320 00

& " & " & & (

& ( / ( # #

9-8-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

As a precautionary measure, Camber Pharmaceuticals, Inc. is voluntarily recalling all unexpired lots of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level. This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N-Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).

FDA - U.S. Food and Drug Administration

13-7-2018

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg to the retail level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), made by the manufacturer – Zhejiang Huahai Pharmaceutical Co. Ltd. -- that is used in the manufacture of the subject product ...

FDA - U.S. Food and Drug Administration

27-7-2018

EU/3/11/868 (Celgene Europe B.V.)

EU/3/11/868 (Celgene Europe B.V.)

EU/3/11/868 (Active substance: Lenalidomide) - Transfer of orphan designation - Commission Decision (2018)5045 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/160/10/T/01

Europe -DG Health and Food Safety

27-6-2018

EU/3/15/1606 (Bayer AG)

EU/3/15/1606 (Bayer AG)

EU/3/15/1606 (Active substance: (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate) - Transfer of orphan designation - Commission Decision (2018)4094 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/184/15/T/02

Europe -DG Health and Food Safety

6-4-2018

EU/3/12/1072 (Le4D Limited)

EU/3/12/1072 (Le4D Limited)

EU/3/12/1072 (Active substance: Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor) - Transfer of orphan designation - Commission Decision (2018)2008 of Fri, 06 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/160/11/T/01

Europe -DG Health and Food Safety